Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | STK33 | Q9BYT3 | 6/20 | 0.35 |
| ▸ | CDK4 | P11802 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871083 | 0.81 | NPC1 (0.36) | NPC1RAB9ASTK33CDK4MEN1 | |
| SCHEMBL13866113 | 0.79 | PKN1 (0.44) | NPC1RAB9ACDK4MEN1KMT2A | |
| SCHEMBL5667203 | 0.78 | RAB9A (0.59) | NPC1RAB9ASTK33CDK4MEN1 | |
| SCHEMBL5666574 | 0.74 | CDK4 (0.34) | NPC1RAB9ASTK33CDK4MEN1 | |
| SCHEMBL13865841 | 0.71 | MGAM (0.52) | NPC1RAB9AMAPK8MAPK9MAPK10 | |
| SCHEMBL8520222 | 0.65 | PARP1 (0.53) | MAPK8MAPK9MAPK10KDM4E | |
| SCHEMBL8520766 | 0.65 | NPC1 (0.46) | NPC1RAB9AMAPK8MAPK9MAPK10 | |
| SCHEMBL13673378 | 0.65 | POLB (0.49) | MEN1KMT2AMAPK8MAPK9MAPK10 | |
| SCHEMBL17591301 | 0.58 | PARP1 (0.50) | MEN1KMT2AMAPK8MAPK9GSK3B | |
| SCHEMBL31663463 | 0.57 | DAO (0.45) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | NPC1 1218/4885RAB9A 1059/4885STK33 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.